Merus Labs International Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Merus Labs International Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10600
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Merus Labs International Inc (Merus Labs International), formerly Merus Labs Inc, a subsidiary of Norgine BV, is a pharmaceutical company that provides medicinal products. The company offers products in the therapeutic areas of cardiovascular, oncology support, women’s health, urology, and infectious disease. Its products include Salagen, a pilocarpine hydrochloride oral tablet used to manage symptoms of xerostomia associated with radiation therapy; Estraderm, a patch medication containing estrogen, which is used to reduce symptoms of menopause, such as hot flashes and vaginal dryness in women, and others. It operates in Luxembourg, British Columbia, the Netherlands, and the US. The company markets its products in Austria, Denmark, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Italy, Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden, Switzerland. Merus Labs International is headquartered in Toronto, Ontario, Canada.

Merus Labs International Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Merus Labs International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Merus Labs International Inc, Medical Devices Deals, 2012 to YTD 2018 10
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 12
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 13
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 14
Merus Labs Acquires Sintrom from Novartis 15
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 16
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 17
Partnerships 18
Merus Labs Enters into Agreement with Vansen Pharma 18
Equity Offering 19
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 19
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 21
Merus Labs Completes Partial Exercise of Underwriter’s Over Allotment Option for Public Offering of Shares for USD63 Million 22
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 23
Merus Labs Raises USD28.7 Million in Public Offering of Shares 24
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 25
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 26
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 27
Asset Transactions 28
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 28
Acquisition 30
Norgine Acquires Merus Labs International 30
Merus Labs International Inc – Key Competitors 32
Merus Labs International Inc – Key Employees 33
Merus Labs International Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
May 11, 2017: Merus Labs Reports Fiscal Q2 2017 Results 35
Feb 14, 2017: Merus Labs Reports Fiscal Q1 2017 Results 37
Other Significant Developments 40
May 04, 2017: Merus Labs Announces Key Milestone for Sintrom Profit Enhancing Initiative 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Merus Labs International Inc, Pharmaceuticals & Healthcare, Key Facts 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Merus Labs International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Merus Labs International Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Merus Labs International Inc, Medical Devices Deals, 2012 to YTD 2018 10
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 12
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 13
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 14
Merus Labs Acquires Sintrom from Novartis 15
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 16
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 17
Merus Labs Enters into Agreement with Vansen Pharma 18
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 19
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 21
Merus Labs Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD63 Million 22
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 23
Merus Labs Raises USD28.7 Million in Public Offering of Shares 24
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 25
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 26
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 27
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 28
Norgine Acquires Merus Labs International 30
Merus Labs International Inc, Key Competitors 32
Merus Labs International Inc, Key Employees 33
Merus Labs International Inc, Subsidiaries 34

List of Figures
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Merus Labs International Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Merus Labs International Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nobilis Health Corp (NHC):企業の財務・戦略的SWOT分析
    Summary Nobilis Health Corp (Nobilis Health), formerly Northstar Healthcare Inc is a healthcare development and management company that offers outpatient surgery and healthcare solutions. The center’s services include surgical services, surgery and critical patient education services. Its surgical s …
  • Bankers Insurance Group:企業の戦略・SWOT・財務分析
    Bankers Insurance Group - Strategy, SWOT and Corporate Finance Report Summary Bankers Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Idexx Laboratories Inc (IDXX):企業の財務・戦略的SWOT分析
    Idexx Laboratories Inc (IDXX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Mitsui E&S Holdings Co., Ltd. (7003):石油・ガス:M&Aディール及び事業提携情報
    Summary Mitsui E&S Holdings Co., Ltd. (Mitsui E&S) is a shipbuilding and engineering product manufacturing company. It has diversified business operations comprising environment recycling, construction of social infrastructure, advanced machinery systems, IT-related activities, ships and oceans, pla …
  • MediWound Ltd (MDWD):医療機器:M&Aディール及び事業提携情報
    Summary MediWound Ltd (MediWound) is a biopharmaceutical company that on develops, manufactures and commercializes novel therapeutics based on its patented proteolytic enzyme technology. Its products address unmet needs in the areas of severe burns, chronic and other hard-to-heal wounds.The company’ …
  • Highmark Inc:企業の戦略的SWOT分析
    Highmark Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • GarrettCom, Inc.:企業の戦略的SWOT分析
    GarrettCom, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Volt Information Sciences Inc (VISI):企業の財務・戦略的SWOT分析
    Volt Information Sciences Inc (VISI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Sinopharm Group Co Ltd (1099):製薬・医療:M&Aディール及び事業提携情報
    Summary Sinopharm Group Co Ltd (Sinopharm), a subsidiary of China National Pharmaceutical Group Corp is a distributor of pharmaceutical and healthcare products. The group provides distribution, logistics and other value-added services to foreign and domestic manufacturers and suppliers of pharmaceut …
  • Penta-Ocean Construction Co Ltd:戦略・SWOT・企業財務分析
    Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cardinal Ethanol LLC (CRDE):企業の戦略的SWOT分析
    Cardinal Ethanol LLC (CRDE) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Klaria Pharma Holding AB (KLAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Klaria Pharma Holding AB (Klaria Pharma) is a developer of fast acting medicinal products that designes, develops and commercializ therapeutics for migraine and cancer related pain. The company’s patented drug delivery platform is an alginate-based polymer film, facilitates quick and dependa …
  • Northam Platinum Limited:企業の戦略・SWOT・財務分析
    Northam Platinum Limited - Strategy, SWOT and Corporate Finance Report Summary Northam Platinum Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Anheuser-Busch InBev SA/NV:企業の戦略・SWOT・財務分析
    Anheuser-Busch InBev SA/NV - Strategy, SWOT and Corporate Finance Report Summary Anheuser-Busch InBev SA/NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Pioneer Distilleries Limited:企業の戦略・SWOT・財務分析
    Pioneer Distilleries Limited - Strategy, SWOT and Corporate Finance Report Summary Pioneer Distilleries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Sensorion SA (ALSEN):企業の財務・戦略的SWOT分析
    Summary Sensorion SA (Sensorion) is a biopharmaceutical company that develops therapies. The company provides treatments for vestibular and cochlear pathologies. It develops drug candidates through its technology platform for the treatment of various therapeutic areas including vestibular neuritis, …
  • ImmunoGen Inc (IMGN):企業の財務・戦略的SWOT分析
    ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • European Medical Contract Manufacturing BV-医療機器分野:企業M&A・提携分析
    Summary European Medical Contract Manufacturing BV (EMCM BV), a subsidiary of Leader Biomedical Group, is a drug company that develops and manufactures sterile medicinal products. The company also manufactures liquids, powders, suspensions and gels. Its products include bone cements for hip and knee …
  • United Therapeutics Corp (UTHR)-医療機器分野:企業M&A・提携分析
    Summary United Therapeutics Corp (UTC) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues including Remodulin (tre …
  • Mochida Pharmaceutical Co Ltd (4534):製薬・医療:M&Aディール及び事業提携情報
    Summary Mochida Pharmaceutical Co Ltd (Mochida) is a pharmaceutical company that develops, manufactures and markets drugs and diagnostic regents. The company's drugs are used for the treatment of arteriosclerosis obliterans, hyperlipidemia, hypertension, angina pectoris, endometriosis, mycosis, thro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆